Lightspeed Takde siapa nak beli saham ni dgn harga murah, kita nak jual je, pasal kaunter ni menipu duit shareholder
----------------

Ini baru betul. Orang yang amat cerdik sedang tunggu jual saham sambil mengutuk saham tersebut supaya jatuh.

Nampak buktinya yang songsang dengan apa sepatutnya.

Realitinya, normal bagi seseorang yang dalam proses nak jual sesuatu saham untuk beri berita yang baik tentang saham itu supaya ia naik dan mengurangkan kerugian.

Yang penting awak dapat beli harga murah.

Lightspeed, OKU_2020 dan 8dragon. Awak telah jual saham awak sebelum ini. Tiada lagi kepentingan.

Sebab itu sekarang badmouth hari-hari kaunter ini supaya awak akan dapat beli pada harga rendah. He He

@OKU_2020 a k.a MDP.

Yang betul hanya awak. Hari-hari cerita hantu yang tak betul. Biar orang cut loss rugi banyak-banyak. Orang lain mampos tak apa. Yang penting awak dapat beli harga murah.

Kalau bukan itu sebabnya, mungkin awak tak akan badmouth hari-hari kaunter ini. Terutama kaunter yang awak badmouth akan gol mengikut kata awak.

Rosak susu kerana nila setitik, Rosak company bukan kerana naysayer dan hater. He He

@OKU_2020 a.k.a. MDP.

Prinsip saya mudah saja. Tak akan cut loss kerana harapan masih ada terhadap Nexgram. Tak rugi selagi tak jual.....

Itulah sebab saya cari maklumat. Hendak dapatkan kepastian utamanya untuk buat keputusan sendiri. Berita itu juga saya sebarkan untuk share kepada rakan-rakan demi melawan naysayer dan hater seperti awak dan seangkatan dengannya.

@OKU_2020. kalau awk memang ada kemampuan mental yang normal, cuba teliti dengan sebenarnya keadaan kewangan Nexgram sekarang.

Adakah ia sebuah syarikat yang lebih teruk keadaannya dari segi FA?

Minta tolong ikhlas pada diri sendiri sekurang-kurangnya.

Tak takut eh.
Saya sekadar yang mampu tak akan biarkan ada MDP atau geng oppurtunist saham yang cuba takut-takutkan orang tanpa fakta betul dan fakta menyokong.

@Singapore88. Eid mubarak

@8dragon. ..... NG has nvr come up with positive notes to attract investors instead Ozura keep on selling as their cost is only 1.5 cents....

--------------------------------------

3. NEXGRAM
Issue price per share ($) Malaysian Ringgit (MYR) 0.0200

@8dragon. No. its from the 3QR 2021 report. Only "my personal comment" come from my analysis.

Please refer to the 3QR 2021 report at:

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3171550

@8dragon. The fake GN3 ghost was spoken lies.
She is using her "fake balls' to do her prediction.

The incoming 4QR 2021 will be better. The capital reduction will be rationalized in the company's accounts. The accumulated losses will change to small retained profit. The cash collected from the ICPS conversion. The revenues expected to increase. The company's shareholder equity on consolidated basis of its shares excluding treasury shares is at 56.47 %. No more GN3 listed issuer risk.

Please refer to:

https://klse.i3investor.com/blogs/mzm511/2021-07-01-story-h1567122502-SOME_ANALYSIS_FROM_THE_3QR_2021_OF_NEXGRAM_0096.jsp

Thank you. Selamat Hari Raya Aidil Adha juga untuk semua yang merayakannya. Maaf Zahir Batin

@Amzar007. Cakap pihak lain asyik nak scam. Kita sendiri scammer buta huruf yang diajar oleh "para guru scammer". He He.

Astrazeneza ada 3 holder bagi setiap jenis vaksin astrazeneza yang diluluskan NPRA.

Bil Registration No. Product name Holder

1 MAL21036009ACZ COVID-19 Vaccine AstraZeneca Solution for Injection ASTRAZENECA SDN. BHD.

2 MAL21076098AZ COVILO Suspension for Injection COVID-19 Vaccine (Vero Cell), Inactivated DUOPHARMA (M) SDN. BHD.

3 MAL21046125ACSZ CoronaVac Suspension for Injection COVID-19 Vaccine (Vero Cell), Inactivated PHARMANIAGA LIFESCIENCE SDN. BHD.

4 MAL21046001AZ COVID-19 Vaccine AstraZeneca Solution for Injection (The product approved by EMA is supplied under the Commercial name: Vaxzevria) KEMENTERIAN KESIHATAN MALAYSIA

5 MAL21066001ACSZ COVID-19 Vaccine AstraZeneca Solution for Injection ASTRAZENECA SDN. BHD.

6 MAL21076097ACZ Janssen COVID-19 Vaccine Suspension for Injection JOHNSON & JOHNSON SDN BHD

7 MAL21066049AZ COVID-19 Vaccine Janssen Suspension for Injection KEMENTERIAN KESIHATAN MALAYSIA

@Amzar007.

Setakat maklumat yang saya ada, tiada pun rekod dalam WHO yang menyatakan astrazeneza dari thailand diluluskan WHO. Bagaimana pula NPRA boleh luluskan astrazeneca dari thailand? Kalau awak ada maklumat boleh kemukakan, boleh kita sama-sama lihat.

Vaksin dari Arab dibuat under collaboration. Bermaksud, CNBG boleh authorize yang pengeluaran vaksin tersebut walaupun dibuat di Arab tetapi under authorization dari pemegang patent yang diluluskan oleh WHO. Sekadar pandangan saya saja.

@hlh1962. Agree.
and other idea is, sometimes the developer of the vaccine itself can't coop with excess demand for the vaccine and colloborate with other manufacturer from other countries to manufacture it.

The same happens to Astrazeneca. We are importing Astrazeneca vaccine from the manufacturer in Thailand.

UAE to begin manufacturing ‘Hayat-Vax’ Covid-19 vaccine
The ‘Life Sciences and Vaccine Manufacturing in the UAE’ is a joint project by the Abu Dhabi-based Group 42 and China’s Sinopharm CNBG

Source: https://gulfbusiness.com/uae-to-begin-manufacturing-covid-19-sinopharm-vaccine/

@hlh1962. Please read this.

Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.

The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

@hlh1962. I just can do my guessing based on this report.
...................

Under the agreement, Sinopharm Group has appointed KIB as the sole distributor for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia, however, both parties WILL SIGN A SEPARATE AGREEMENT in regards to specific product category, price, purchase price and payment method.

Fahaman yang lagi sesat ialah kutuk kutuk kutuk saham yang kita pegang. Cut loss supaya rugi banyak.

Ini bukan fahaman yang sesat, tetapi fahaman orang kurang siuman. He He

Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.

The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).

Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.

The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

Earlier this year, Sinopharm entered into a joint venture with UAE-based G42 to produce the Sinopharm Covid-19 vaccines in the country under the Hayat-Vax brand.

The made-in-UAE vaccine was the first Covid-19 vaccine to be produced in the Arab world.

"The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in the UAE. Hence, we are confident that it will be well-received and accepted by the Malaysian people as an effective vaccine towards the global fight against the Covid-19 pandemic," said Kuah.

Kanger has also been authorised by G42 to be the product registration holder and distributor of the Hayat-Vax vaccine in Malaysia.

On behalf of G42 Medications, Kanger said it had submitted applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency for the Hayat-Vax vaccine to be used in Malaysia.

Relax. Tak rugi selagi tak cut loss.

@18Kharmoni. Yang beli kanger kat pasaran tu bukan semuanya newbie. Bapak kepada investor/trader pun ada saya rasa.Itulah volume besar.

Arsenewenger8383 .... kanger will submit sinophram from UAE to get approval from NPRA?? Hehehe... how long need to wait again?
----------------------
On behalf of G42 Medications, Kanger has submitted the necessary applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency (NPRA) for the Hayat-Vax vaccine to be used in the country.

ADA KITA CONFIRM BILA DIA SUBMIT. Mungkin semasa MOU dengan Sabah dahulu pun kita TAK TAHU...

Kalau Kanger jadi main distributor kepada duopharma????? Bagaimana pula. Ada kemungkinankah?????. Memandangkan Kanger sebelum ini lebih awal menandatangani sebagai distributor bagi pihak sinopharm.

@Noobie123.

Under the agreement, Sinopharm Group has appointed KIB as the sole distributor for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia, however, both parties WILL SIGN A SEPARETE AGREEMENT in regards to specific product category, price, purchase price and payment method.

(Remarks: This agreement shall take effect for a period of three years effective from 25 September 2020 until 24 September 2023)

Source: https://www.msn.com/en-my/news/national/kanger-sinopharm-inks-agreement-for-covid-19-vaccine-distribution-in-malaysia/ar-BB19x0Lr

AND SEE: This one is the:

OTHERS KANGER INTERNATIONAL BERHAD ("KANGER" OR "THE GROUP") EXECUTION HEAD OF AGREEMENT

The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products

Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.

The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).

The Board of Directors of Kanger (“Company”) wishes to announce that Kanger Medical International Sdn. Bhd., a wholly-owned subsidiary of the Company had, on 19 July 2021 entered into Head of Agreement with Sparmak Medical Equipment Trading LLC for purchase of inactivated SARS-COV-2 Vaccines (Vero Cell) vaccine developed by Beijing Institute of Biological Products Co. Ltd., an affiliate of SINOPHARM CNBG.

Please refer to the full announcement as attached.

This announcement is dated 19 July 2021.

Source: https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3176295

4.1 Quantity and specification of the Products
Quantity: Five Million (5,000,000) doses with an option to buy an additional Five Million (5,000,000) doses.
Specification: SARS COV-2 vaccine (Vero cell) inactivated, 6.5 U/0.5ml in prefilled syringe or vial (as per availability) and pack size either 2 doses per vial per box or Single dose per vial per box (as per availability). The Product is manufactured by Gulf Pharmaceutical Industries Julphar in the United Arab Emirates (HAYAT-VAX), i.e. G42 Medications Trading LLC (“Manufacturer”).

1. Sinopharm COVID vaccine: the world needs to keep using it, even if it’s less effective than Pfizer

Source: https://theconversation.com/sinopharm-covid-vaccine-the-world-needs-to-keep-using-it-even-if-its-less-effective-than-pfizer-162207

2. Health officials have stressed that all the COVID-19 vaccines are effective, saying “the best vaccine is the one that’s available”.

Source: https://www.aljazeera.com/news/2021/7/16/how-effective-are-chinas-sinovac-and-sinopharm-vaccines

@NicmannNg. It's true. Just to give an idea from a different angle. He He.

The final conclusion is, only the demand and supply of the shares in the market will determine the share price.

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be SOME COMPANIES who WILL BE APPROVED to bring in SOME PRIVATE VACCINES from China. I know Sinopharm and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

Report 3: Covid-19: Those who want to bring in Sinopharm vaccine can register it with NPRA, says Khairy.

(Source: https://www.thestar.com.my/news/nation/2021/05/21/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy )

Report 6: The states are free to negotiate with drug makers Moderna and Sinopharm, whose vaccines have been approved by the World Health Organization . Khairy said that as long as the vaccines have been given the green light by the National Pharmaceutical Regulatory Agency, the states are free to procure them.

(Source: https://www.freemalaysiatoday.com/category/nation/2021/06/03/state-govts-free-to-purchase-moderna-sinopharm-vaccines/ )

Report 2: Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”

(Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/ )

Report 6: The states are free to negotiate with drug makers Moderna and Sinopharm, whose vaccines have been approved by the World Health Organization . Khairy said that as long as the vaccines have been given the green light by the National Pharmaceutical Regulatory Agency, the states are free to procure them.

(Source: https://www.freemalaysiatoday.com/category/nation/2021/06/03/state-govts-free-to-purchase-moderna-sinopharm-vaccines/ )

Khairy also mentioned that Covid-19 vaccines will enter the private market by August. He said that private vaccination will help the government ramp up the national Covid-19 vaccination programme, as those who are able to pay for the vaccines will be able to do so.

“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be SOME COMPANIES who WILL BE APPROVED to bring in SOME PRIVATE VACCINES from China. I know Sinopharm and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

@Noobie123. The facts is the second one not yet approved by WHO. If Kanger relating to that one, it could be a late comer. By the way, I can't give the answer about which vaccines referred to Kanger.

@Noobie123. Okay. Sorry

@Noobie123. I intended to stress that it is an agreement, not MOU.

yingzhe17 Duopharma is only packing. Distributor will be Kanger. Wait for press release.
--------------------
Hope to see that you have a reliable source of information. Thanks.

Noobie123 1. MOU is not an agreement. It is just a letter to state understandings.
----------------------------------

The distributorship agreement has been signed by Kanger and Sinopharm Group Hunan Changde Medical Co Ltd. Instead, its not an MOU.
.........
2. Kanger has entered a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.

Under the agreement, Sinopharm Group has appointed KIB as the sole distributor for the vaccines, medical devices and products in Malaysia. KIB will also undertake the marketing and promotion of Sinopharm Group's products in Malaysia, however, both parties will sign a separate agreement in regards to specific product category, price, purchase price and payment method.

(Remarks: This agreement shall take effect for a period of three years effective from 25 September 2020 until 24 September 2023)

Source: https://www.msn.com/en-my/news/national/kanger-sinopharm-inks-agreement-for-covid-19-vaccine-distribution-in-malaysia/ar-BB19x0Lr

TEKNIK HARAPAN.... He He

I'm looking for further news about the vaccine distributorship for Kanger. Is it a totally failed plan or not. Just curious about the report given by KJ, on .... SOME COMPANIES

..... I think that there will be SOME COMPANIES who will be approved to bring in some private vaccines from China.

By the way, the RI theme is underway. @Fong Kh. I beg to differ.

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.

AFTER ALL. TAYOR.

...... The immunisation programme now has a total of six vaccines within its portfolio: Sinopharm, Pfizer-BioNTech, AstraZeneca, Sinovac, Cansino, and Johnson & Johnson.

Cuma timbul persoalan. Adakah bekalan untuk swasta dan kerajaan negeri semuanya mesti dibekalkan melalui GLC yang dilantik? Bagaimana dengan permohohan untuk kelulusan sinopharm dari pihak lain selain daripada Duopharma. Adakah ditolak sepenuhnya????

@Noobie123.

The predictions only been made by a reference to the news. I'm not insider nor political agent. He He

Report 5: 24 June 2021.
“I also anticipate by about August, we will have a private vaccine market. So right now, it’s difficult for private because vaccines are in short supply. But by August, I think that there will be SOME COMPANIES who will be approved to bring in some private vaccines from China. I know SINOPHARM and all that are going to be registered here,” Khairy added.

“That’s also part of the plan. I’ve been talking to the Ministry of Health to ensure that the private market by August can take off to help us.”

Source: https://codeblue.galencentre.org/2021/06/24/khairy-projects-40-population-fully-vaccinated-by-end-august/

@18KHarmoni. I am good. Portfolio getting better. I'm looking for further news about the vaccine distributorship for Kanger. Is it a totally failed plan or not.

By the way, the RI theme is underway. The vaccine plan is a bonus as been said before by a number of us....
INVESTING IS PLAYING A RISKY GAME. He He.

Pharma dan Duopharma down. Ini mesti ada udang sebalik batu.
Takkan Kanger tak boleh gap up sikit kot. He He

Yes....